Eagle Pharmaceuticals Reports Third Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 27c
November 9, 2021 6:51 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.56, $0.27 worse than the analyst estimate of $0.83. Revenue for the quarter came in at $39.9 million versus the consensus estimate of $46.4 million.
For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.
... More